How the miRoncol Early Cancer Risk Assessment Works
A simple blood draw. Advanced molecular analysis. Meaningful insights you and your physician can use to guide preventive care.
Step 1:
Blood Collection
The process begins with a standard blood draw at a participating clinic. No special preparation is required.
This makes the test accessible and easy to integrate into annual checkups, executive health programs, or preventive health plans.
Step 2:
microRNA Analysis
The blood sample is analyzed for microRNA biomarkers — short, non-coding RNA molecules that regulate gene expression and can change when cancer begins developing at the cellular level.
These biomarkers are sensitive indicators of early biological activity, sometimes detectable before symptoms appear or imaging reveals abnormalities.
Step 3:
AI-Powered Pattern Recognition
Using large-scale human data, our platform applies AI-driven algorithms to identify shared microRNA signal patterns associated with common solid tumour types.
This approach provides a multi-cancer early risk assessment in real time, giving individuals and physicians an additional layer of insight to support preventive decisions.
Step 4:
Report Generation
A concise report is created showing whether cancer-linked molecular signals were detected.
Signal Detected
Discuss with your physician about possible next steps, such as further screening or imaging.
No Signal Detected
Provides reassurance and supports ongoing preventive health planning.
All reports are shared directly through participating clinics and are intended for review with a healthcare provider.
What to Remember
- This is an early risk assessment tool, not a diagnostic test.
- It is designed to complement existing screening programs, not replace them.
- Results should always be interpreted in the context of physician-led care.
Your Next Step
The miRoncol Real-time Multi-Cancer Risk Assessment is currently available on a limited basis.
